Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.
about
Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatmentMilnacipran for neuropathic pain and fibromyalgia in adultsSerotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndromeThe search for novel analgesics: targets and mechanismsEULAR revised recommendations for the management of fibromyalgia.Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.Interpreting effect sizes and clinical relevance of pharmacological interventions for fibromyalgia.Management of fibromyalgia syndrome: review of evidence.Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.Sodium oxybate for the treatment of fibromyalgia.Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia.Tramadol for the treatment of fibromyalgia.Pregabalin for pain in fibromyalgia in adults.Pharmacotherapy for fibromyalgia.Does increasing steps per day predict improvement in physical function and pain interference in adults with fibromyalgia?A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patientsFibromyalgia: a primer for the anesthesia community.Meeting them where they are: Using the Internet to deliver behavioral medicine interventions for painPalmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies.Complementary and alternative exercise for fibromyalgia: a meta-analysis.Duloxetine: a review of its safety and efficacy in the management of fibromyalgia syndromeExtension trial of qigong for fibromyalgia: a quantitative and qualitative study.Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgiaHealth care costs in patients with fibromyalgia on pregabalin vs. duloxetine.Fibromyalgia: from pathophysiology to therapy.Coanalgesics for chronic pain therapy: a narrative review.A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.Pregabalin for the treatment of fibromyalgia.Monotherapy or combination therapy for fibromyalgia treatment?Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.Including a range of outcome targets offers a broader view of fibromyalgia treatment outcome: results from a retrospective review of multidisciplinary treatment.Sleep disturbance and chronic widespread pain.Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use.Attentional performance may help to identify duloxetine responders in chronic pain fibromyalgia patients.Challenges of implementing fibromyalgia treatment guidelines in current clinical practice.Interest in yoga among fibromyalgia patients: an international internet survey.Juvenile fibromyalgia in an adolescent patient with sickle cell disease presenting with chronic pain.Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.Comment on: 'Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia'.
P2860
Q21296574-089CE8A4-6134-4564-A421-4095320E35F7Q24201093-4D639753-B4E0-47BE-A0C7-E50B25C071FAQ24201799-F118BC15-0670-4985-85C6-2B2E62E3B8E2Q24288817-C76A65D5-422A-4859-9285-EB01FAF3AFD5Q30249155-D7C9A014-498A-430D-A79A-5E54F566581FQ33747253-D2FAE8EC-F093-48FA-A639-EE37DAAEF0FAQ33938142-FDD910B0-C464-47CC-B48B-52FE00A639A8Q33938302-1F895B12-3EFA-4139-9659-C843E29A1A16Q34035333-644899DB-D10A-4EA5-9EE0-2488AF1CBF6AQ34193082-2CF0C59E-84EE-4AEA-8DF5-B2345E9499BDQ34379796-32A1D444-051B-4CCF-A1A5-572EF01E496CQ34472775-29C412D5-11E6-415A-83EF-DBB9E20DACF9Q34541472-AC7CA0D3-DE58-4996-BC21-041D9845F47CQ35092347-FFA108F3-C9C8-4CDB-B047-FC145BA9023AQ35322619-C917E181-91A7-4EAF-B529-3A8AC33CE3FEQ35986975-29449791-99A4-4EA0-A5FF-889096FEB17FQ36174493-BD02B057-21B0-4216-9D7A-F24C850FD8E7Q36178274-981C59F0-8917-4239-895F-67C72F635470Q36365821-DEC7DCA2-4124-497A-86DF-493E29307121Q36739178-53F71F9B-DC33-4F7A-817D-8B5839DA0BD7Q36866408-6C5B248F-1E1D-436C-A4E1-09C611F574C6Q37166680-6DD81AFE-C47F-4B34-A2BD-13CD0876443DQ37690358-02856B6B-60EF-440C-905E-B9F2DD81039AQ37880281-29E497B6-B2D3-4555-8BB2-398ED489D684Q37902512-EF8A942D-EBEC-4C28-BF26-78A74353E489Q37959164-EC115024-6BB4-41A8-9814-B9FBD0F951BAQ38020236-593CF080-C577-4AA5-BE50-53DFF4BA54E2Q38020946-8D3D1A53-74C4-470C-AC7B-E9296FF64689Q38027051-7AF96FE3-5B75-4DE8-A83D-BE64AE4A99AAQ38090730-057DB315-DD6F-4B5A-99A2-4AB4F359DBDEQ38123453-2F4A0E61-B011-4E22-A331-7580460A76D2Q38325708-F4B732BD-4ECF-47DD-B03F-95F027692A26Q38831882-9C913EB2-DB03-46DC-9911-B32A190484BFQ38877302-55B8B600-259F-468D-B084-0D58270B9A9BQ38986630-01AAA92F-95D5-4F61-8569-244FE7C464E1Q39340760-F758191D-6B6A-4B0E-A5BA-9E4A33F9E219Q41095151-1D83FA34-DDDB-494B-BE89-AB979E54B715Q41634746-57115E7F-EB62-4E5D-B34E-F63C3252B6C5Q44198587-2EC0E35E-56BC-408F-AB2E-822EFD85CB8BQ45721208-4EA81110-0B5B-4FAE-9D8A-E9C8A2D50687
P2860
Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@en
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@nl
type
label
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@en
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@nl
prefLabel
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@en
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@nl
P1433
P1476
Comparative efficacy and harms ...... alin in fibromyalgia syndrome.
@en
P2093
Claudia Sommer
Frank Petzke
P304
P356
10.1016/J.JPAIN.2010.01.002
P577
2010-04-24T00:00:00Z